ReviewHeliyon2022
The efficacy of Chinese patent medicine intervention on blood glucose and lipid in prediabetes: A meta-analysis.
Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Traditional Chinese medicine use and risk of type 2 diabetes mellitus among patients with prediabetes: a population-based cohort study.Chinese medicine · 2025Article
- Application of Luteolin in Neoplasms and Nonneoplastic Diseases.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study was to analyze the efficacy and safety of Chinese patent medicine in the treatment of blood glucose, blood lipid and insulin resistance in prediabetic patients through a meta-analysis of clinical trials. Methods: Randomized controlled trials of Chinese patent medicine in the treatment of prediabetes were searched in the databases of CNKI, WanFang, VIP, CBM, PubMed, Web of Science and Embase using the computer with the search deadline on June 2, 2022. The two researchers independently screened the literatures based on the inclusion and exclusion criteria, and the fasting blood glucose, postprandial blood glucose, glycated hemoglobin, insulin resistance index, blood lipids, prediabetes reversal rate and diabetes conversion rate were used as outcome indicators. The quality of the study was evaluated according to the Cochrane scale, and data were analyzed by RevMan software. Results: Sixteen clinical trial studies were eventually fitted into, and a meta-analysis was conducted on the included studies, and the final results showed as follows: Compared with conventional lifestyle intervention, the remedy of Chinese patent medicine intervention in prediabetes patients had significant effects on the outcome indicators, such as fasting blood glucose [ Conclusions: The results indicated that Chinese patent medicine intervention could ameliorate the outcome indicators of prediabetes with significant efficacy and good safety. Its therapeutic effect was mainly manifested in blood glucose, insulin, body weight, and diabetes conversion rate. Chinese patent medicine maybe a promising avenue for prediabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.